Article: MDS Nordion Launches Theryttrex in Europe.

ROSTOK, Germany, April 22 /PRNewswire/ --

- Radiopharmaceutical-grade yttrium-90 used in production of first radioimmunotherapeutic product approved for use in EU

ROSTOK, Germany, April 22 /PRNewswire/ --

MDS Nordion today announced the launch of Theryttrexa, MDS Nordion's radiopharmaceutical grade yttrium-90 (Y-90), at the German Congress of Nuclear Medicine held in Rostok, Germany. Theryttrex is used as a precursor to radiolabel Zevalin(R)(1), the first radioimmunotherapeutic product approved in the EU for the treatment of non- Hodgkin's Lymphoma. Radioimmunotherapeutics are manufactured by labelling, or linking, radioactive isotopes to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!